financetom
Business
financetom
/
Business
/
Mosaic Lowers Phosphate Volume Guidance for Q2, Fiscal 2025
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mosaic Lowers Phosphate Volume Guidance for Q2, Fiscal 2025
Jun 6, 2025 5:30 AM

08:07 AM EDT, 06/06/2025 (MT Newswires) -- The Mosaic Co. ( MOS ) said Friday it now expects Q2 phosphate sales volume in the range of 1.5 million to 1.6 million tonnes, down from its prior range of 1.7 million to 1.9 million tonnes.

Production volume for fiscal 2025 is now anticipated to range between 7 million and 7.3 million tonnes, compared with the previous range of 7.2 million to 7.6 million tonnes, the company said.

Mosaic said it continues to expect potash sales volume for Q2 in the range of 2.3 million to 2.5 million tonnes, adding that fiscal 2025 production volume outlook also remains unchanged in the range of 9 million to 9.4 million tonnes.

Phosphate price outlook for Q2 was lifted to the $650-to-$670 per tonne range from $635 to $655 anticipated previously while potash prices are anticipated to be stable, according to the company.

Mosaic's stock was down nearly 5% in recent Friday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln
Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln
Nov 13, 2025
Overview * Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement * Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year * Palatin ( PTN ) completes $18.2 mln public offering, regains NYSE American compliance Outlook * Company plans IND submission and Phase 1 trial for PL7737 in first...
HLS Therapeutics Narrows Q3 Loss as Vascepa Scripts Climb
HLS Therapeutics Narrows Q3 Loss as Vascepa Scripts Climb
Nov 13, 2025
07:43 AM EST, 11/13/2025 (MT Newswires) -- HLS Therapeutics ( HLTRF ) said Thursday that third-quarter net loss narrowed slightly as revenue rose. Net loss improved to US$3.92 million, or $0.12 per share, from a loss of $4.84 million, or $0.15 per share in the prior year period. Revenue decreased 4% to $13.5 million, primarily due to lower Clozaril Canada...
Century Therapeutics Q3 net loss widens, despite lower costs
Century Therapeutics Q3 net loss widens, despite lower costs
Nov 13, 2025
Overview * Century Therapeutics ( IPSC ) reports Q3 net loss of $34.4 mln, compared to $31.2 mln last year * R&D expenses decreased to $22.5 mln in Q3, primarily due to reduced personnel costs Outlook * Century plans to initiate IND-enabling studies for T1D program by end of 2025 * Company expects to advance CNTY-308 into clinical studies in...
Xilio Therapeutics' Q3 collaboration revenue rises
Xilio Therapeutics' Q3 collaboration revenue rises
Nov 13, 2025
Overview * Xilio Q3 collaboration revenue rises to $19.1 mln from $2.3 mln year-over-year * Net loss for Q3 widens to $16.3 mln from $14.0 mln year-over-year * Company anticipates cash runway into Q1 2027 Outlook * Xilio plans to submit IND for XTX501 in mid-2026 * Company anticipates cash runway into Q1 2027 * Xilio seeks partner for vilastobart...
Copyright 2023-2026 - www.financetom.com All Rights Reserved